We are comparing a new point-of-care CAR T-cell treatment to a standard commercial option for patients with relapsed or refractory Non-Hodgkin Lymphoma. The goal is to see if the new therapy can improve survival and safety outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed/Refractory Non-Hodgkin Lymphoma is a type of cancer that affects the lymphatic system, where the lymphoma returns after treatment or does not respond to initial therapies. It can manifest in various forms and may require different treatment approaches.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.